MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/ccm.0000000000006564

Медицинская библиотека · Critical care medicine · 2025

Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial.

Almeida Thiago M L, Freitas Flávio G R, Figueiredo Rodrigo C, Houly Sandra G, Azevedo Luciano C P, Cavalcanti Alexandre B, Damiani Lucas P, Svicero Bianca S, Souza Maria A, Bustamante Cíntia L S, Ramos Fernando J S, Alves Rafael S V, Atallah Fernanda C, Jackiu Míriam, Pacheco Eduardo S, Schmidt Raysa C, Serra Felipe S C, Tomotani Daniere Y V, Zampieri Fernando G, Machado Flávia R, BRICNET

СтатьяРандомизированное исследованиеКлиническое исследование II фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVES

Platelets play a critical role in the inflammatory response and coagulation. We aimed to evaluate whether the use of acetylsalicylic acid (ASA) would reduce the intensity of organ dysfunction in septic patients.

DESIGN

Randomized, blinded, parallel-group, placebo-controlled trial.

SETTING

Five general ICUs in Brazil.

PATIENTS: Adults with sepsis for no longer than 48 hours who had at least one severe organ dysfunction (lactate > 4 mmol/L, platelets < 100,000/mm3, Pao2/Fio2 ratio < 200, or septic shock).

INTERVENTIONS: Patients were randomized to receive 200 mg of ASA or placebo for 7 days.

MEASUREMENTS AND MAIN

RESULTS

The primary outcome was the change in the Sequential Organ Failure Assessment (SOFA) score between day 0 and day 7 or date of discharge/death. Safety outcomes were major bleeding and the number of blood transfusions within 14 days. The planned sample size was 218 with interim safety analyses after enrolling 109 and 163 patients. The study was discontinued due to higher frequency of major bleeding in the ASA group. We included 166 patients (ASA: 82 patients, placebo: 84). In the adjusted analysis, there was no difference in the SOFA change between the groups (mean placebo to ASA group difference, 0.60; 95% CI, -0.55 to 1.75; p = 0.30). There were no differences in any of the secondary outcomes. In the intervention group, there were a higher number of serious adverse events (9 [11%] vs. 1 [1.2%]; p = 0.009) and major bleeding (8 [8.5%] vs. 1 [1.2%]; p = 0.02).

CONCLUSIONS

In this population of septic patients, ASA did not reduce the intensity of organ dysfunction. ASA increased the risk of severe bleeding compared with placebo.

Для цитирования: Almeida Thiago M L, Freitas Flávio G R, Figueiredo Rodrigo C, Houly Sandra G, Azevedo Luciano C P, Cavalcanti Alexandre B, Damiani Lucas P, Svicero Bianca S, Souza Maria A, Bustamante Cíntia L S, Ramos Fernando J S, Alves Rafael S V, Atallah Fernanda C, Jackiu Míriam, Pacheco Eduardo S, Schmidt Raysa C, Serra Felipe S C, Tomotani Daniere Y V, Zampieri Fernando G, Machado Flávia R, BRICNET. Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial.. Critical care medicine. 2025. DOI: 10.1097/ccm.0000000000006564.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.